GlassScriptPhysician profile
Paul Dennis Maher
NPI 1750348942
$3,669.96
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,297 · 2020: $502 · 2021: $519 · 2022: $284 · 2023: $22.66 · 2024: $44.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $66.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $66.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $823.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $578.86 | 2019-2023 | |
| Pfizer INC. | $421.52 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $242.94 | 2019 | |
| Abbott Laboratories | $233.55 | 2019-2024 | Cardiomems |
| Biotronik INC. | $203.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $164.65 | 2019-2022 | |
| Amarin Pharma, INC. | $155.28 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.58 | 2019-2020 | |
| Edwards Lifesciences Corporation | $138.64 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $126.67 | 2019-2020 | |
| Esperion Therapeutics, INC. | $101.02 | 2020-2021 | |
| Akcea Therapeutics, INC. | $89.02 | 2019-2020 | |
| Boston Scientific Corporation | $81.38 | 2021-2024 | Emblem Mri S-Icd |
| Merck Sharp & Dohme LLC | $43.61 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43.38 | 2019 | |
| Gilead Sciences, INC. | $22.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $21.51 | 2019 | |
| Lundbeck LLC | $21.06 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.